YoshitakeMasuda

Counsel

(T) + 81.3.6800.1806

Connect:

Share

Yoshitake Masuda has more than 20 years experience in international and domestic business transactions with a focus on mergers and acquisitions, joint ventures, and strategic alliances. He represents clients in various industries such as life sciences, energy, automobiles, and information technology. Yoshitake also has broad experiences in commercial transactions, such as international sales and distribution agreements and intellectual property agreements.

In addition, Yoshitake advises clients who are operating businesses in Japan on corporate governance matters and legal compliance matters under Japanese law. The legal compliance matters he covers includes laws and guidelines for the life sciences industry and for labor and employment. Further, his experience includes internal investigations and international and domestic dispute resolution.

Prior to joining Jones Day, he was a partner at a Japanese law firm in Tokyo. He also has two years of experience as an in-house legal counsel at a general trading company in Japan and has experience as a board member of a Japanese listed company.

Experience

  • Mitsui Chemicals establishes new polypropylene compounds company in NetherlandsJones Day advised Mitsui Chemicals, Inc. in the establishment of Mitsui Prime Advanced Composites Europe B.V. in the Netherlands.
  • TonenGeneral Sekiyu combines with JX GroupJones Day advised TonenGeneral Sekiyu K.K. in connection with the business integration with JX Group, which forms the largest oil refiner in Japan.
  • Takeda Pharmaceutical undergoes investigation involving alleged misconduct relating to investigator-initiated sponsored study on hypertension medicineJones Day, as a third-party organization, conducted an investigation for Takeda Pharmaceutical Company Limited in a matter involving alleged misconduct relating to an investigator-initiated sponsored study on its hypertension medicine, known as Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J).
  • TonenGeneral Sekiyu acquires Mitsui & Co.'s 89.93 percent interest in Mitsui Oil for JPY24.9 billion (US$241.3 million)Jones Day advised TonenGeneral Sekiyu K.K. in its 89.93 percent interest in the stock of Mitsui Oil Co., Ltd. for JPY24.9 billion (US$241.3 million).
  • Cardinal Health acquires leading patient product portfolio from Medtronic for $6.1 billionJones Day advised Cardinal Health on the acquisition of Medtronic's Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses for $6.1 billion in cash.
  • Timken acquires BEKA Lubrication for $165 millionJones Day advised The Timken Company in its $165 million acquisition of BEKA Lubrication (BEKA), a leading global supplier of automatic lubrication systems.
  • ANSYS acquires OPTISJones Day advised ANSYS, Inc., the global leader and innovator of engineering simulation software, on its acquisition of OPTIS, a premier provider of software for scientific simulation of light, human vision, and physics-based visualization.
  • Mahle acquires thermal division from Delphi Automotive for $727 millionJones Day advised Mahle GmbH in the acquisition of the thermal division of automotive supplier Delphi PLC for $727 million.
  • Atlas Holdings completes first phase of purchase of NCR Corporation's Interactive Printer Solutions DivisionJones Day represented affiliates of Atlas Holdings, LLC in its acquisition of the Interactive Printer Solutions ("IPS") division of NCR Corporation.
  • RHJ International sells 100% equity interest in Phoenix Resort to Sega SammyJones Day advised RHJ International SA in connection with its sale of its 100% equity interest in Phoenix Resort K.K., a multi-faceted hotel, resort, and conference complex, to Sega Sammy Inc., a Japanese listed corporation.
  • Cabot sells its Supermetals business for $400 millionJones Day advised Cabot Corporation in the $400 million sale of its Supermetals business to Global Advanced Metals.
  • Avon completes $90 million sale of ownership interest in Avon Japan business to TPG Capital affiliateJones Day advised Avon Japan, a Jasdaq listed subsidiary of Avon Products Inc. and global manufacturer and marketer of beauty and related products, in connection with the $90 million sale of its 74.67% ownership interest in its Avon Japan business to a fund managed by TPG Capital.
    • View All

    October 2019 Jones Day Publications

    Japan Legal Update Vol. 49 | September–October 2019

    August 2019 Newsletters

    Japan Legal Update Vol. 48 | July–August 2019

    April 2019 Jones Day Publications

    Japan Legal Update | Vol. 46

    January 2019 Jones Day Publications

    ジョーンズ・デイ・ホワイト・ペーパー：FCPA 2018年次レビュー

    September 2018 Jones Day Publications

    Japan Legal Update | Vol. 40

    September 2018 アラート

    ジョーンズ・デイ・コメンタリー：米国巡回区控訴裁判所がFCPAの適用範囲を拡張することを否定

    July 2018 Jones Day Publications

    Japan Legal Update | Vol. 38

    June 2018 Jones Day Publications

    Japan Legal Update | Vol. 37

    June 2018 アラート

    ジョーンズ・デイ・コメンタリー：欧州委員会による補充的保護証明書に関する検討

    March 2018 Jones Day Publications

    ジョーンズ・デイ・ホワイト・ペーパー：ペルーとアルゼンチン、新たな腐敗防止法制が企業をリスクにさらす
    View All

    Speaking Engagements

    • March 2017
      ジョーンズ・デイ ライフサイエンスセミナー：FDAによる法執行の最新動向
    • March 2016
      ジョーンズ・デイ ライフサイエンスセミナー：リバース・ペイメントと後発品参入に関する独占禁止法上の重要問題
    • September 2015
      ライフサイエンス業界における法執行及びコンプライアンスの最新動向
    • May 2015
      医薬品企業法務研究会：個人情報保護法平成27年改正の概要
    • November 2012
      M&Aセミナー：メキシコにおけるM&A及び合弁事業－主要な考慮事項
    • March 2012
      Directors' Liability Seminar & Workshop, Belgian Luxembourg Chamber of Commerce in Japan
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.